MA63848B1 - Méthodes de traitement d'une splénomégalie - Google Patents

Méthodes de traitement d'une splénomégalie

Info

Publication number
MA63848B1
MA63848B1 MA63848A MA63848A MA63848B1 MA 63848 B1 MA63848 B1 MA 63848B1 MA 63848 A MA63848 A MA 63848A MA 63848 A MA63848 A MA 63848A MA 63848 B1 MA63848 B1 MA 63848B1
Authority
MA
Morocco
Prior art keywords
splenomegaly
methods
treatment
therapeutic methods
provides therapeutic
Prior art date
Application number
MA63848A
Other languages
English (en)
French (fr)
Other versions
MA63848A1 (fr
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma, Inc. filed Critical Telios Pharma, Inc.
Publication of MA63848A1 publication Critical patent/MA63848A1/fr
Publication of MA63848B1 publication Critical patent/MA63848B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MA63848A 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie MA63848B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08

Publications (2)

Publication Number Publication Date
MA63848A1 MA63848A1 (fr) 2024-04-30
MA63848B1 true MA63848B1 (fr) 2024-10-31

Family

ID=76788747

Family Applications (3)

Application Number Title Priority Date Filing Date
MA63848A MA63848B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA57226A MA57226B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA69153A MA69153A1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA57226A MA57226B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA69153A MA69153A1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie

Country Status (15)

Country Link
EP (2) EP3980069A4 (cg-RX-API-DMAC10.html)
JP (2) JP7771064B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220130151A (cg-RX-API-DMAC10.html)
CN (1) CN114423457A (cg-RX-API-DMAC10.html)
AU (1) AU2021205484A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013646A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164063A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022010592A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220374A (cg-RX-API-DMAC10.html)
IL (1) IL294582A (cg-RX-API-DMAC10.html)
JO (1) JOP20220168A1 (cg-RX-API-DMAC10.html)
MA (3) MA63848B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022008490A (cg-RX-API-DMAC10.html)
TN (1) TN2022000185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021142257A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12662484B2 (en) 2016-08-17 2026-06-23 Shenzhen Targetrx, Inc. Substituted piperidines as bruton's tyrosine kinase inhibitors
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly
US12697333B2 (en) 2020-01-08 2026-08-04 Telios Pharma, Inc. Methods of treating splenomegaly
WO2022266285A1 (en) * 2021-06-16 2022-12-22 Telios Pharma Inc. Treatment of symptoms associated with myeloproliferative neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
JP2025527431A (ja) * 2022-08-25 2025-08-22 ビーワン メディシンズ ワン ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
US20160122365A1 (en) * 2014-10-03 2016-05-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
US20160122365A1 (en) * 2014-10-03 2016-05-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Also Published As

Publication number Publication date
CR20220374A (es) 2023-01-25
AU2021205484A1 (en) 2022-08-18
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
BR112022013646A2 (pt) 2022-10-04
JP7771064B2 (ja) 2025-11-17
CA3164063A1 (en) 2021-07-15
CO2022010592A2 (es) 2022-10-31
TN2022000185A1 (en) 2024-04-01
JP2023509968A (ja) 2023-03-10
MA57226A1 (fr) 2023-02-28
MX2022008490A (es) 2022-10-13
EP3980069A1 (en) 2022-04-13
MA69153A1 (fr) 2025-07-31
IL294582A (en) 2022-09-01
JP2026027353A (ja) 2026-02-18
EP3980069A4 (en) 2022-08-17
KR20220130151A (ko) 2022-09-26
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JOP20220168A1 (ar) 2023-01-30
MA63848A1 (fr) 2024-04-30

Similar Documents

Publication Publication Date Title
MA63848A1 (fr) Méthodes de traitement d'une splénomégalie
EP3755805A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL
MA52861B1 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple
MA44764A (fr) Méthodes de traitement de patients présentant une hypercholestérolémie familiale
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
ATE347376T1 (de) Behandlung von allergien
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EP4121022A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUS INFECTION
MA62935B1 (fr) Méthodes de traitement ou de prévention de l'amyotrophie spinale
EP3570835A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF IMMUNINFLAMMABLE DERMAL DISEASES
EP4215531A4 (en) COMPOUND FOR PREVENTING AND TREATING LIVER DISEASES AND ITS PHARMACEUTICAL USE
EP4489746A4 (en) Extended-release pharmaceutical compositions for the treatment of eye conditions
EP4469033A4 (en) Pharmaceutical compositions for the treatment of pain
EP4103179A4 (en) Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4489858A4 (en) Extended-release pharmaceutical compositions for the treatment of eye conditions
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
EP4574171A4 (en) Pharmaceutical composition for the treatment and/or prevention of renal cystic ciliopathy
EP1726313A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
DE60131100D1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
FR3097743B1 (fr) Produit de combinaison pour aider au maintien des défenses naturelles de l’organisme
Kiełbasa et al. Searching for the Holy Grail among ear drops